Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

• Status: Completed
• Trial end date: 2017-09-04
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CJ HealthCare Corporation; HK inno.N Corporation
• Treatments: Amlodipine; Rosuvastatin Calcium; Valsartan

Criteria

Inclusion Criteria:

• Aged between 19 and 74 years

• Patient with dyslipidemia and hypertension

Exclusion Criteria:

• At screening, siSBP ≥ 200 mmHg or siDBP ≥ 120mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL

• At screening, siSBP difference is ≥ 20 mmHg or siDBP difference is ≥10 mmHg

• Secodary hypertension

• Type I or uncontrolled diabetes mellitus (HbA1c ≥ 9 %)